Anti-miR-93-5p therapy prolongs sepsis survival by restoring the peripheral immune response

• Published in: The Journal of clinical investigation 2023-07, Vol.133 (14)
• Main Authors: Dragomir, Mihnea P, Fuentes-Mattei, Enrique, Winkle, Melanie, Okubo, Keishi, Bayraktar, Recep, Knutsen, Erik, Qdaisat, Aiham, Chen, Meng, Li, Yongfeng, Shimizu, Masayoshi, Pang, Lan, Liu, Kevin, Liu, Xiuping, Anfossi, Simone, Zhang, Huanyu, Koch, Ines, Tran, Anh M, Mohapatra, Swati, Ton, Anh, Kaplan, Mecit, Anderson, Matthew W, Rothfuss, Spencer J, Silasi, Robert, Keshari, Ravi S, Ferracin, Manuela, Ivan, Cristina, Rodriguez-Aguayo, Cristian, Lopez-Berestein, Gabriel, Georgescu, Constantin, Banerjee, Pinaki P, Basar, Rafet, Li, Ziyi, Horst, David, Vasilescu, Catalin, Bertilaccio, Maria Teresa S, Rezvani, Katayoun, Lupu, Florea, Yeung, Sai-Ching, Calin, George A
• Format: Article
• Language: English
• Subjects: Care and treatment; Development and progression; Gene expression; Genetic aspects; Health aspects; Immune response; Immunology; Infectious disease; MicroRNA; Sepsis
• ISSN: 1558-8238; 0021-9738; 1558-8238
• DOI: 10.1172/JCI158348

Sepsis remains a leading cause of human death and currently has no pathogenesis-specific therapy. Hampered progress is partly due to a lack of insight into deep mechanistic processes. In the last decade, deciphering the functions of small non-coding microRNAs (miRNAs) in sepsis pathogenesis became a dynamic research topic. To screen for new miRNA targets for sepsis therapeutics, we used human samples for miRNA array from peripheral blood mononuclear cells from sepsis patients and controls, blood samples from two cohorts of sepsis patients, and multiple animal models: mouse cecum ligation-puncture (CLP)-induced sepsis, mouse viral miRNA challenge, and baboon Gram-positive and Gram-negative sepsis models. miR-93-5p met the criteria for a therapeutic target, being overexpressed in baboons that died early after induction of sepsis, downregulated in humans who survived after sepsis, and correlated with negative clinical prognosticators for sepsis. Therapeutically, inhibiting miR-93-5p prolonged the overall survival of mice with CLP-induced sepsis, with a stronger effect in older mice. Mechanistically, anti-miR-93-5p therapy reduced inflammatory monocytes and increased circulating effector memory T cells, especially the CD4+ subset. AGO2-immunoprecipitation in miR-93-knockout T cells identified important regulatory receptors, such as CD28, as direct miR-93-5p target genes. In conclusion, miR-93-5p is a potential therapeutic target in sepsis through regulating both innate and adaptive immunity with possibly more benefit for the elderly than the young patients.